We are highly suspicious that someone who has attended the centre has clovid 19 virus. It has therefore been decided by the Chair that we have to shut for the rest of this week. Sue will be contacting everyone who has been in the centre in the last 2 weeks to see if they have… Read more »
Posts By: Karen Jones
Preventing the Spread of Coronavirus
Oxfordshire MS Therapy Centre Preventing the Spread of Coronavirus Information Sheet Coronavirus is a virus similar to the flu virus, which has the same symptoms and effects & spreads the same way. Our Centre users are generally more vulnerable to developing a more serious level of symptoms, therefore, prevention is more important. Coronavirus is a… Read more »
Coronavirus
Coronavirus Public Information: Please follow all guidance being provided by HM Government and NHS regarding the containment of the virus. The news is changing rapidly, please keep up to date with the national and local developments. At the Centre we have provided additional hand sanitisers, tissues, waste bins, and displayed posters reminding people to regularly… Read more »
Coronavirus and MS
Source Multiple Sclerosis International Federation: The coronavirus and MS – what you need to know The ‘novel coronavirus’ (recently named by the World Health Organization as COVID-19) is a respiratory illness that has not previously been seen in humans. COVID-19 is a strain of coronavirus that was first detected in China in December 2019, and has… Read more »
MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity
Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found. The results were published in an article, “Effect of switching from natalizumab to moderate- vs high-efficacy DMT in… Read more »
Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports
Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show. Masitinib, formerly known as AB1010, is an oral therapy that inhibits the activity of cells in the innate immune system, specifically mast… Read more »
January 100 club winners
100 club winners for January 1st prize: Shirley Ray 2nd prize: Julia Gower 3rd prize: Sue Doran
Coronavirus
Coronavirus – Statement from the MS National Therapy Centres If you have travelled to any of the countries affected by the Corona virus please follow the protocol for self-isolation for 14 days. If you have direct contact with anyone who either has Coronavirus or who has been to a HIGH RISK area, please stay away… Read more »
NHS ‘rapid response teams’ to help sick and older people at home.
Source The Guardian: Plan aims to relieve strain on hospitals by offering a visit within two hours. Older people and the very sick will be visited within two hours by a “rapid response team” of health and care staff under new NHS plans to relieve the strain on overcrowded hospitals. The teams will include nurses, physiotherapists, occupational… Read more »
Online Fatigue- management course
Source MS Society: This online course will help you find ways to manage your MS fatigue and explain it to other people. It’s made up of 6 sessions that should take around 20 minutes each. In between the sessions are exercises for you to do, to help you think about your own fatigue. The course works… Read more »
